KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Minority Interest (2019 - 2025)

Historic Minority Interest for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $3.2 billion.

  • Royalty Pharma's Minority Interest fell 537.32% to $3.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 billion, marking a year-over-year decrease of 537.32%. This contributed to the annual value of $3.4 billion for FY2024, which is 455.36% down from last year.
  • As of Q3 2025, Royalty Pharma's Minority Interest stood at $3.2 billion, which was down 537.32% from $3.2 billion recorded in Q2 2025.
  • Royalty Pharma's Minority Interest's 5-year high stood at $5.0 billion during Q1 2021, with a 5-year trough of $3.1 billion in Q1 2025.
  • For the 5-year period, Royalty Pharma's Minority Interest averaged around $3.8 billion, with its median value being $3.6 billion (2023).
  • Its Minority Interest has fluctuated over the past 5 years, first tumbled by 1937.76% in 2023, then plummeted by 167.1% in 2024.
  • Quarter analysis of 5 years shows Royalty Pharma's Minority Interest stood at $4.5 billion in 2021, then fell by 12.85% to $3.9 billion in 2022, then dropped by 8.71% to $3.6 billion in 2023, then fell by 4.55% to $3.4 billion in 2024, then dropped by 5.57% to $3.2 billion in 2025.
  • Its Minority Interest was $3.2 billion in Q3 2025, compared to $3.2 billion in Q2 2025 and $3.1 billion in Q1 2025.